Hemogenyx Pharmaceuticals PLC (LON:HEMO) was up 7.7% during mid-day trading on Monday . The stock traded as high as GBX 2.29 ($0.03) and last traded at GBX 2.10 ($0.03), approximately 887,153 shares traded hands during mid-day trading. A decline of 89% from the average daily volume of 8,010,000 shares. The stock had previously closed at GBX 1.95 ($0.03).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
The company has a current ratio of 12.36, a quick ratio of 12.36 and a debt-to-equity ratio of 415.66. The firm has a 50-day moving average of GBX 2.12 and a 200-day moving average of GBX 2.55. The stock has a market capitalization of $7.95 million and a price-to-earnings ratio of -5.50.
About Hemogenyx Pharmaceuticals (LON:HEMO)
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants.
Further Reading: Limitations of analyzing profit margin
